AZD7442 (tixagevimab/cilgavimab) is the first long-acting antibody drug that has demonstrated it can be used in this way, reducing the risk of symptomatic COVID-19 by 77% compared to placebo in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback